| Literature DB >> 25093995 |
Marta L DeDiego1, Jose L Nieto-Torres1, Jose M Jimenez-Guardeño1, Jose A Regla-Nava1, Carlos Castaño-Rodriguez1, Raul Fernandez-Delgado1, Fernando Usera2, Luis Enjuanes3.
Abstract
Coronavirus (CoV) infection is usually detected by cellular sensors, which trigger the activation of the innate immune system. Nevertheless, CoVs have evolved viral proteins that target different signaling pathways to counteract innate immune responses. Some CoV proteins act as antagonists of interferon (IFN) by inhibiting IFN production or signaling, aspects that are briefly addressed in this review. After CoV infection, potent cytokines relevant in controlling virus infections and priming adaptive immune responses are also generated. However, an uncontrolled induction of these proinflammatory cytokines can lead to pathogenesis and disease severity as described for SARS-CoV and MERS-CoV. The cellular pathways mediated by interferon regulatory factor (IRF)-3 and -7, activating transcription factor (ATF)-2/jun, activator protein (AP)-1, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and nuclear factor of activated T cells (NF-AT), are the main drivers of the inflammatory response triggered after viral infections, with NF-κB pathway the most frequently activated. Key CoV proteins involved in the regulation of these pathways and the proinflammatory immune response are revisited in this manuscript. It has been shown that the envelope (E) protein plays a variable role in CoV morphogenesis, depending on the CoV genus, being absolutely essential in some cases (genus α CoVs such as TGEV, and genus β CoVs such as MERS-CoV), but not in others (genus β CoVs such as MHV or SARS-CoV). A comprehensive accumulation of data has shown that the relatively small E protein elicits a strong influence on the interaction of SARS-CoV with the host. In fact, after infection with viruses in which this protein has been deleted, increased cellular stress and unfolded protein responses, apoptosis, and augmented host immune responses were observed. In contrast, the presence of E protein activated a pathogenic inflammatory response that may cause death in animal models and in humans. The modification or deletion of different motifs within E protein, including the transmembrane domain that harbors an ion channel activity, small sequences within the middle region of the carboxy-terminus of E protein, and its most carboxy-terminal end, which contains a PDZ domain-binding motif (PBM), is sufficient to attenuate the virus. Interestingly, a comprehensive collection of SARS-CoVs in which these motifs have been modified elicited full and long-term protection even in old mice, making those deletion mutants promising vaccine candidates. These data indicate that despite its small size, E protein drastically influences the replication of CoVs and their pathogenicity. Although E protein is not essential for CoV genome replication or subgenomic mRNA synthesis, it affects virus morphogenesis, budding, assembly, intracellular trafficking, and virulence. In fact, E protein is responsible in a significant proportion of the inflammasome activation and the associated inflammation elicited by SARS-CoV in the lung parenchyma. This exacerbated inflammation causes edema accumulation leading to acute respiratory distress syndrome (ARDS) and, frequently, to the death of infected animal models or human patients.Entities:
Keywords: Coronavirus; Envelope protein; Inflammation; Innate immunity; MERS-CoV; SARS-CoV
Mesh:
Substances:
Year: 2014 PMID: 25093995 PMCID: PMC4261026 DOI: 10.1016/j.virusres.2014.07.024
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Coronavirus proteins affecting innate immune responses.
| Protein | CoV | Immune function | References |
|---|---|---|---|
| Nsp1 | SARS-CoV | Antagonizes type I IFN production and signaling by inducing host mRNAs shut off, promoting the degradation of host mRNAs and preventing phosphorylation of STAT1 | |
| Upregulates CCL5, CXCL10, and CCL3 in human lung epithelial cells via the activation of NF-κB | |||
| Nsp3 | SARS-CoV | Prevents IFN production by blocking IRF3 phosphorylation, most probably by interacting with STING | |
| MHV | Antagonizes type I IFN | ||
| MERS-CoV | Antagonizes type I IFN | ||
| Nsp7 | SARS-CoV | Antagonizes type I IFN | |
| Nsp15 | SARS-CoV | Antagonizes type I IFN | |
| S | SARS-CoV | Induces the expression of IL6, IL8, CXCL10 and TNF through NF-κB activation in macrophages | |
| M | SARS-CoV | Blocks IFN-β production by impairing the formation of TRAF3–TANK–TBK1/IKKɛ complex | |
| N | SARS-CoV | Antagonizes type I IFN production by blocking IRF-3 phosphorylation | |
| Activates NF-κB and upregulates the expression of IL-6 | |||
| Activates AP-1 | |||
| Induces the expression of IL8 via AP-1 activation | |||
| 3a | SARS-CoV | Downregulates the expression of the type I IFN receptor (IFNAR), leading to a blockade on type I IFN signaling | |
| Increases NF-κB and JNK activity and upregulates TNF, IL8 and CCL5 production | |||
| 3b | SARS-CoV | Antagonizes type I IFN production by blocking IRF-3 phosphorylation. Inhibits IFN signaling | |
| Induces transcriptional activity of AP-1, through activation of JNK and ERK pathways, leading to CCL2 upregulation | |||
| 6 | SARS-CoV | Antagonizes type I IFN production by blocking IRF-3 phosphorylation | |
| Inhibits IFN signaling by blocking the nuclear translocation of the transcription factor STAT1 | |||
| 7a | SARS-CoV | Activates NF-κB and upregulates the expression of the proinflammatory mediators IL8 and CCL5 | |
| Nsp3 | NL63 | Antagonizes type I IFN | |
| Nsp1 | MHV | Antagonizes type I IFN | |
| N | MHV | Acts as an interferon antagonist and prevents RNA degradation by inhibiting RNaseL activity | |
| 2 | MHV | Antagonizes type I IFN signaling and prevents activation of the cellular endoribonuclease RNase L | |
| 5a | MHV | Antagonizes type I IFN | |
| 4a | MERS-CoV | Block interferon induction at the level of MDA5 activation presumably by direct interaction with double-stranded RNA | |
| 4b | MERS-CoV | Antagonizes type I IFN | |
| 7 | TGEV | Reduces the expression of genes involved in the immune response, the interferon response, and inflammation | |
| 7a | FIPV | Antagonizes type I IFN |
Fig. 1Effect of coronavirus proteins on cellular signaling pathways associated with the innate immune response. PAMPs such as ssRNA, dsRNA, or viral proteins, trigger the activation of transcription factors leading to proinflammatory cytokine and type I IFN induction. PAMPs activate the PKR, leading to eIF2α phosphorylation and host translation inhibition, and 2′–5′ OAS, leading to RNase L triggering and RNA degradation. The activation of RIG-I and MDA-5 triggers the activation of IRF-3, IRF-7 and NF-κB through MAVS. In addition, TLRs activate the MyD88 and TRIF-dependent pathways, activating the transcription factors IRF-3, IRF-7, NF-κB, and AP-1. The steps inhibited or promoted by CoV proteins are indicated in red boxes. Beside these proteins, other proteins that inhibit or promote the IFN signaling and production and inflammatory cytokine expression, through an identified mechanism, are indicated in Table 1.
Fig. 2Effect of coronavirus proteins on type I IFN signaling. The IFN-α and IFN-β proteins are secreted from the cell and amplify the IFN response activating the ISGF3 complex formed by STAT1, STAT2 and IRF-9, leading to the expression of the interferon-stimulated genes (ISG). The steps inhibited or promoted by CoV proteins are indicated in red boxes.
Fig. 3Engineered rSARS-CoVs-MA15 with point mutations and deletions in E gene. The organization of E protein is shown. E protein sequence is divided into three domains: the amino terminal (N-terminal), the transmembrane and the carboxy-terminal (C-terminal). The figure illustrates the deletions and point mutations engineered within E protein. The asterisk (*) indicates mutations in the residues S3A, V5L, T9A, T11A. Gray box at the bottom indicates mutant virulence: (+) indicates a virulent phenotype and (−) indicates an attenuated phenotype.
Fig. 4Recombinant SARS-CoVs with E protein PBM truncated or mutated by reverse genetics. SARS-CoV E protein sequence and its corresponding domains are shown at the top. Below, sequences corresponding to the end of E protein are shown in boxes for the different virus mutants. SARS-CoV-E-wt, wild type sequence. In SARS-CoV-E-ΔPBM and SARS-CoV-E-mutPBM virus mutants, E protein PBM was eliminated by the introduction of deletions or point mutations, reducing or keeping the full protein length, respectively. In SARS-CoV-E-potPBM, four amino acids of E protein were replaced by alanine, to generate a new potential PBM. Red boxes highlight PBMs within E protein. Gray box on the right indicates the virulence of the mutants: (+) indicates a virulent phenotype and (−) indicates an attenuated phenotype.
Fig. 5Structure of SARS-CoV E protein proteolipidic ion channel. Phospholipids are represented in blue, and E protein monomers are shown as red cylinders. Note that lipid head groups (blue ellipses) also face the ion channel lumen.
Fig. 6Effect of SARS-CoV E protein ion channel activity in lung pathology. The lung histopathology in mice infected with a virus displaying (EIC+) or lacking (EIC−) E protein ion channel activity at 4 days post infection (dpi) is shown at the top. Lung sections were analyzed by hematoxylin and eosin staining at an original magnification of 20×. Airspaces where edema was accumulated are indicated with asterisks. Immunofluorescence staining of lung sections, and detail of bronchiolar epithelia at 4 dpi, at a magnification of 40× and 190×, respectively is shown at the bottom. Lung epithelia was labeled using an anti Na+/K+ ATPase antibody (green) and SARS-CoV infection was tracked with an anti-N protein antibody (red). Nuclei are shown in blue. Desquamated epithelial cells and cell debris are observed in lung airways after EIC+ virus infection (white arrows).